title: Safe and effective booster immunization using DTaP in teenagers.
abstract: The incidence of reported cases with pertussis has increased in young adults in Japan and the lack of additional booster immunizations containing pertussis components is suspected to be one of the causal reasons. Instead of DT immunization at 11-12 years of age, safety and immunogenicity were investigated using 0.2 ml and 0.5 ml of DTaP. 176 subjects in DTaP 0.5ml, 178 in DTaP 0.2 ml, and 197 in DT 0.1 ml groups were enrolled in clinical trial. The relative risk of local reactions in the DTaP 0.2 ml group compared to the DT 0.1 ml group was 1.13 (95% CI: 0.97-1.30), and that of the DTaP 0.5 ml to the DT 0.1 ml group was 1.34 (95% CI: 1.18-1.53). The relative risks of local pain and heat were 1.62 (95% CI: 1.33-1.98) and 1.59 (95% CI: 1.19-2.13), respectively, in the DTaP 0.5 ml group compared to the DT 0.1 ml group. Sero-positive rates against PT and FHA were 54% and 82% before immunization and increased to >95% for both after vaccination with no significant difference in GMT. Instead of the scheduled DT program, 0.2 ml of DTaP was acceptable and demonstrated efficient immunogenicity.
authors.affiliation: National Fukuoka Hospital, Department of Pediatrics, Japan.
authors.forename: Kenji
authors.initials: K
authors.lastname: Okada
authors.forename: Takako
authors.initials: T
authors.lastname: Komiya
authors.forename: Akihiko
authors.initials: A
authors.lastname: Yamamoto
authors.forename: Motohide
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kazunari
authors.initials: K
authors.lastname: Kamachi
authors.forename: Takashi
authors.initials: T
authors.lastname: Nakano
authors.forename: Takao
authors.initials: T
authors.lastname: Nagai
authors.forename: Nobuhiko
authors.initials: N
authors.lastname: Okabe
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Kamiya
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Nakayama
mesh_terms: D000293:Adolescent; D000907:Antibodies, Bacterial / Q000097:blood; D002648:Child; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage* / Q000009:adverse effects / Q000276:immunology; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D015994:Incidence; D007564:Japan; D008297:Male; D014917:Whooping Cough / Q000276:immunology / Q000517:prevention & control*
chemical_list: D000907:Antibodies, Bacterial; D015721:Diphtheria-Tetanus-Pertussis Vaccine